Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia This study is to examine which dose of DA-3031(PEG-G-CSF) has similar efficacy and safety compared to daily G-CSF in chemotherapy-induced neutropenia.

• Pays Korea, Republic of
• Organes Aucun
• Spécialités Aucune

Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia This study is to determine whether once-per-cycle DA-3031(PEG-G-CSF) is not inferior to daily G-CSF in chemotherapy-induced neutropenia.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune